shortagewatch

Home / Companies / Organon

Company family · HQ US

Organon: medicine shortages

OGN · NYSE

As of 2 Nov 2026, 40 Organon products have a reported shortage across 11 countries, covering 20 medicines.

Products short40rank #49 of 464
Medicines20active ingredients
Countries11/16
New in 90 days21+10 vs market pace
Typical duration34 daysmedian so far
Manufacturing74%demand-driven 9%

Where

United States1Canada4Italy3Spain2Ireland2Austria1Belgium2Czechia2Norway5Sweden13Japan5

Which therapeutic classes

Dermatologicals8Musculoskeletal system6Respiratory system5Cardiovascular system5Genito-urinary system and sex hormones4Systemic hormones4Digestive tract and metabolism3Nervous system2

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
OrganonOrganon: Manufacturing problem 17 (42%)42%Organon: Increased demand 2 (5%)5%Organon: Active ingredient shortage 2 (5%)5%Organon: Commercial decision or withdrawal 2 (5%)5%Organon: Not stated 17 (42%)42%All companiesAll companies: Manufacturing problem 4,896 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,220 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

Latest changes

All changes

No changes recorded yet. Changes are tracked from our daily snapshots.

Open shortages over time

788931 Oct2026-10-31: 81 Nov2026-11-01: 82 Nov2026-11-02: 8

Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.

When its current shortages began

05101520Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 1NovDec: 0Jan ’26: 0Feb: 0FebMar: 0Apr: 0May: 1MayJun: 4Jul: 1Aug: 1AugSep: 6Oct: 12Nov: 2Nov

Long-run trend in Canada

Canada dashboard
0122537502021: 171720212022: 343420222023: 404020232024: 212120242025: 151520252026: 16162026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz603Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Organon40

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 603 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 150 / 73Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Organon: 40 / 20Organon

Further right: more products short. Higher: more different medicines affected.

Medicines short

Download CSV
MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Etoricoxib59 Oct 2026Not stated7/16
Betamethasone410 May 2026Not stated7/16
Betamethasone426 Aug 2026Manufacturing problem5/16
Montelukast317 Nov 2025Not stated13/16
Multienzymes (Lipase, Protease etc.)38 Jun 2026Active ingredient shortage7/16
Atorvastatin and Ezetimibe23 Jul 2026Manufacturing problem6/16
Finasteride215 Sep 2026Manufacturing problem2/16
Finasteride212 Oct 2026Manufacturing problem8/16
Alendronic Acid and Colecalciferol121 Nov 2026Manufacturing problem5/16
Betamethasone and Antibiotics129 Sep 2026Not stated2/16
Desloratadine120 Oct 2026Not stated7/16
Etonogestrel15 Nov 2026Not stated1/16
Ezetimibe111 Nov 2026Not stated9/16
Levodopa and Decarboxylase Inhibitor115 Sep 2026Manufacturing problem4/16
Losartan12 Oct 2026Not stated6/16
Mianserin12 Aug 2024Manufacturing problem1/16
Mometasone1not givenNot stated1/16
Mometasone119 Nov 2026Not stated3/16
Simvastatin and Ezetimibe11 Sep 2026Manufacturing problem8/16
Tibolone13 Dec 2026Not stated2/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.